440 related articles for article (PubMed ID: 35781526)
1. Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.
Zabihi M; Lotfi R; Yousefi AM; Bashash D
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1585-1606. PubMed ID: 35781526
[TBL] [Abstract][Full Text] [Related]
2. Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
Santamaria D; Ortega S
Front Biosci; 2006 Jan; 11():1164-88. PubMed ID: 16146805
[TBL] [Abstract][Full Text] [Related]
3. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
4. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
5. Current concepts in neuro-oncology: the cell cycle--a review.
Dirks PB; Rutka JT
Neurosurgery; 1997 May; 40(5):1000-13; discussion 1013-5. PubMed ID: 9149259
[TBL] [Abstract][Full Text] [Related]
6. The CDK inhibitor NtKIS1a is involved in plant development, endoreduplication and restores normal development of cyclin D3; 1-overexpressing plants.
Jasinski S; Riou-Khamlichi C; Roche O; Perennes C; Bergounioux C; Glab N
J Cell Sci; 2002 Mar; 115(Pt 5):973-82. PubMed ID: 11870216
[TBL] [Abstract][Full Text] [Related]
7. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human.
Lee YM; Sicinski P
Cell Cycle; 2006 Sep; 5(18):2110-4. PubMed ID: 16969111
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H interaction.
Chiu HC; Huang WR; Liao TL; Chi PI; Nielsen BL; Liu JH; Liu HJ
J Biol Chem; 2018 Aug; 293(32):12542-12562. PubMed ID: 29907572
[TBL] [Abstract][Full Text] [Related]
10. Negative regulators of cyclin-dependent kinases and their roles in cancers.
Lee MH; Yang HY
Cell Mol Life Sci; 2001 Nov; 58(12-13):1907-22. PubMed ID: 11766887
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
[TBL] [Abstract][Full Text] [Related]
12. The driving power of the cell cycle: cyclin-dependent kinases, cyclins and their inhibitors.
Hives M; Jurecekova J; Holeckova KH; Kliment J; Sivonova MK
Bratisl Lek Listy; 2023; 124(4):261-266. PubMed ID: 36598318
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the "Cdk-centric" view of the mammalian cell cycle.
Malumbres M
Cell Cycle; 2005 Feb; 4(2):206-10. PubMed ID: 15655365
[TBL] [Abstract][Full Text] [Related]
14. A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression.: Unlocking cellular and biochemical mechanisms.
Asghar A; Chohan TA; Khurshid U; Saleem H; Mustafa MW; Khursheed A; Alafnan A; Batul R; Bin Break MK; Almansour K; Anwar S
Chem Biol Interact; 2024 Apr; 393():110940. PubMed ID: 38467339
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.
Mikhail S; Albanese C; Pishvaian MJ
Am J Pathol; 2015 May; 185(5):1185-97. PubMed ID: 25747534
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
18. Impairment of rat postnatal lung alveolar development by glucocorticoids: involvement of the p21CIP1 and p27KIP1 cyclin-dependent kinase inhibitors.
Corroyer S; Schittny JC; Djonov V; Burri PH; Clement A
Pediatr Res; 2002 Feb; 51(2):169-76. PubMed ID: 11809910
[TBL] [Abstract][Full Text] [Related]
19. Role of cyclinT/Cdk9 complex in basal and regulated transcription (review).
Napolitano G; Majello B; Lania L
Int J Oncol; 2002 Jul; 21(1):171-7. PubMed ID: 12063565
[TBL] [Abstract][Full Text] [Related]
20. Control of G1 progression by D-type cyclins: key event for cell proliferation.
Kato JY
Leukemia; 1997 Apr; 11 Suppl 3():347-51. PubMed ID: 9209386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
